How about a possible defense brief (Motion to dismiss)?
For informational purposes only (shits and giggles).
UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
DEFENDANTS’ MOTION TO DISMISS PLAINTIFF’S COMPLAINT
INTRODUCTION
Plaintiff’s complaint is lengthy, exhibit-heavy, and rhetorically charged, but it fails to meet the pleading standards required for federal securities manipulation claims. While Plaintiff attempts to attribute conduct to individual market participants by referencing specific MPIDs, the Complaint still does not plead actionable manipulation, scienter, loss causation, or economic plausibility with the particularity required by Rule 9(b) and the Private Securities Litigation Reform Act (“PSLRA”). The Complaint relies on pattern interpretation, editorialized tape narratives, and small notional trading activity that is fully consistent with lawful market making. Because Plaintiff substitutes inference for proof, the Complaint should be dismissed.
LEGAL STANDARD
Claims alleging market manipulation sound in fraud and are subject to Federal Rule of Civil Procedure 9(b) and the PSLRA. Plaintiff must plead with particularity the who, what, when, where, and how of the alleged misconduct, including facts giving rise to a strong inference of scienter. Conclusory allegations, statistical impressions, and visual pattern recognition are insufficient. Plaintiff must also plead loss causation by plausibly linking alleged misconduct to a concrete economic loss.
ARGUMENT
I. The Complaint Fails to Plead Actionable Market Manipulation
Market manipulation requires transactions intended to create an artificial price. Lawful quoting activity, order updates, and liquidity provision do not qualify. Plaintiff’s Complaint relies primarily on Level II screenshots and annotated trade tape examples, asserting that ordinary quote behavior constitutes spoofing, layering, and tape painting. These allegations describe how the market appeared, not how it was manipulated.
The cited examples involve minimal notional amounts, often measured in hundreds or a few thousand dollars. Such activity cannot plausibly support a multi-year market manipulation scheme. Courts routinely reject manipulation claims where the alleged conduct lacks economic magnitude or market impact.
II. Defendant-Specific Allegations Remain Legally Insufficient
Plaintiff does attempt to separate conduct by MPID, primarily attributing bid-side behavior to GTSM and ask-side behavior to NITE. However, MPID-level attribution is not enough.
The Complaint does not plead:
• whether the orders were proprietary trades or customer facilitation
• whether the same account placed and canceled the orders
• whether orders were non-bona fide at entry
• whether any defendant intended not to execute
• whether any defendant realized profit
Rule 9(b) requires account-level attribution and intent, not MPID labeling. Identifying an MPID does not establish that the defendant engaged in deceptive conduct. This failure is fatal.
III. Scienter Is Not Plausibly Alleged
Plaintiff asserts intent through repetition and pattern interpretation, not facts. There are no allegations of internal communications, directives, whistleblowers, supervisory failures, or prior regulatory findings. The Complaint does not exclude lawful explanations such as inventory management, customer order handling, or algorithmic quote updates.
Under Tellabs, the inference of lawful market making is more compelling than the inference of fraud. Plaintiff therefore fails to plead scienter.
IV. Naked Short Selling and Reg SHO Allegations Are Deficient
Plaintiff relies on short volume data and FTD spikes to suggest illegal naked short selling. Courts have repeatedly held that short volume and FTDs, without more, do not establish wrongdoing. Plaintiff does not allege failure to locate, failure to close out, or violations tied to specific proprietary trades by any defendant.
These allegations fail as a matter of law.
V. Plaintiff Fails to Plead Loss Causation
The Complaint alleges price suppression but offers no methodology linking alleged conduct to economic loss. There is no event study, regression analysis, or isolation of the alleged misconduct from lawful market forces. Assertions that the stock “would have been higher” are insufficient under Dura Pharmaceuticals.
VI. No Plausible Artificial Price Is Alleged
Section 9(a)(2) requires pleading of an artificial price created by manipulative conduct. Plaintiff alleges price weakness but does not plead artificiality. Market prices that reflect supply, demand, liquidity, and investor sentiment are not artificial merely because the issuer dislikes the result.
VII. Standing and Reliance Are Defective
Plaintiff, as an issuer, does not plead transactional reliance. Allegations of market-wide harm belong, if at all, to investors. Plaintiff does not allege direct reliance or injury sufficient to confer standing under Rule 10b-5.
VIII. Punitive Damages Are Unavailable
Punitive damages are not recoverable under federal securities laws. Plaintiff’s demand should be stricken.
IX. Injunctive Relief Is Unsupported
The Complaint alleges past conduct only and pleads no facts showing ongoing or imminent harm. Injunctive relief is therefore unavailable.
CONCLUSION
Plaintiff’s Complaint relies on inference, narrative, and visual interpretation rather than transaction-level facts. Even crediting its attempt at MPID-specific pleading, it fails to allege scienter, artificial price, loss causation, or economically plausible manipulation. Because these defects cannot be cured by amendment without discovery Plaintiff is not entitled to, the Complaint should be dismissed.
AI
Market Data 
Markets 
